<SEC-DOCUMENT>0001213900-26-062191.txt : 20260528
<SEC-HEADER>0001213900-26-062191.hdr.sgml : 20260528
<ACCEPTANCE-DATETIME>20260528170628
ACCESSION NUMBER:		0001213900-26-062191
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260528
FILED AS OF DATE:		20260528
DATE AS OF CHANGE:		20260528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASCENTAGE PHARMA GROUP INTERNATIONAL
		CENTRAL INDEX KEY:			0002023311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42484
		FILM NUMBER:		261037724

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
		BUSINESS PHONE:		86 512 8555 7777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		68 XINQING ROAD
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			SUZHOU , JIANGSU
		PROVINCE COUNTRY:   	F4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea029265001-6k_ascentage.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>under the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">For the month of <B>May 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Commission File Number: 001-42484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><I>(Translation of Registrant&rsquo;s name into English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>68 Xinqing Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Suzhou Industrial Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Suzhou, Jiangsu</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">On May 28,
2026, Ascentage Pharma Group International issued an announcement entitled &ldquo;Purchase of Shares by the Trustee for the Purpose of
the 2022 RSU Scheme&rdquo;. A copy of the press release is furnished as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit Title</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 91%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea029265001ex99-1_ascentage.htm">Announcement dated May 28, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Date: May 28, 2026</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Dajun Yang</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Dajun Yang</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029265001ex99-1_ascentage.htm
<DESCRIPTION>ANNOUNCEMENT DATED MAY 28, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; text-align: right"><FONT STYLE="color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0pt; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.05pt; color: #231F20"><FONT STYLE="color: Black"><I>Hong
Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,
make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
from or in reliance upon the whole or any part of the contents of this announcement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 253px; height: 80px"></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black"><B>ASCENTAGE PHARMA GROUP INTERNATIONAL</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="font-size: 10pt; color: Black">&#20126;&#30427;&#37291;&#34277;&#38598;&#22296;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><I>(Incorporated
in the Cayman Islands with limited liability)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><B>(Stock
Code: 6855)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><B>VOLUNTARY
ANNOUNCEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><B>PURCHASE
OF SHARES BY THE TRUSTEE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><B>FOR
THE PURPOSE OF THE 2022 RSU SCHEME</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #231F20"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20"><FONT STYLE="color: Black">This
announcement is made by Ascentage Pharma Group International (the &ldquo;<B>Company</B>&rdquo;) on a voluntary basis. Reference is made
to the announcements of the Company dated June 23, 2022, July 14, 2022, October 21, 2022, October 25, 2022, October 26, 2022, October
27, 2022, October 28, 2022, October 31, 2022, May 8, 2023, November 13, 2023, November 14, 2023, November 16, 2023, February 2, 2024,
September 2, 2024, October 25, 2024, March 31, 2025, April 8, 2025, April 30, 2025, June 27, 2025, November 27, 2025, December 30, 2025,
April 20, 2026, April 30, 2026 and May 27, 2026 (the &ldquo;<B>Announcements</B>&rdquo;) in relation to, among other things, (i) the
adoption of and amendments to the 2022 RSU Scheme; (ii) the initial grant and the further grants of the 2022 Awards thereunder; and (iii)
the purchase of existing Shares by the Trustee on-market for the purpose of the 2022 RSU Scheme. Unless otherwise defined, capitalized
terms used herein shall have the same meanings as those defined in the Announcements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20"><FONT STYLE="color: Black">On May
28, 2026, the Trustee purchased a total of 50,000 existing Shares (the &ldquo;<B>Purchased Shares</B>&rdquo;) on-market for the purpose
of the 2022 RSU Scheme to satisfy the RSUs upon vesting. Details of the Purchased Shares and the latest information about the Shares
held by the Trustee under the Scheme are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 0.5pt; width: 52%">Purchase date</TD>
    <TD STYLE="text-align: center; padding-top: 0.5pt; width: 10%">:</TD>
    <TD STYLE="padding-top: 0.5pt; width: 38%"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">May 28, 2026</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 0.4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Total number of the Purchased Shares</TD>
    <TD STYLE="text-align: center">:</TD>
    <TD STYLE="text-align: justify">50,000 Shares</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 0.45pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.45pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.45pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 4.55pt">Percentage of the Purchased Shares to the total number
    of issued Shares as at the date of this announcement</TD>
    <TD STYLE="text-align: center; padding-top: 4.55pt">:</TD>
    <TD STYLE="padding-top: 4.55pt">Approximately 0.0134%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 0.45pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.45pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.45pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 4.55pt">Total consideration paid for the Purchased Shares <BR>
(excluding all related expenses, transaction levy, brokerage, tax, duties and levies)</TD>
    <TD STYLE="text-align: center; padding-top: 4.55pt">:</TD>
    <TD STYLE="padding-top: 4.55pt"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">HK$1,909,800</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; padding-top: 0.45pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; text-align: center; padding-top: 0.45pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.45pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 3.05pt">Average consideration per Purchased Share<BR>
 (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)</TD>
    <TD STYLE="text-align: center; padding-top: 3.05pt">:</TD>
    <TD STYLE="padding-top: 3.05pt">Approximately HK$38.196</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 0.35pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0.35pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.35pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-top: 4.55pt; padding-right: 1.9pt">Total number of existing Shares purchased by the Trustee on-market for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases</TD>
    <TD STYLE="text-align: center; padding-top: 4.55pt; padding-right: 1.9pt">:</TD>
    <TD STYLE="padding-top: 4.55pt; padding-right: 1.9pt">2,315,000 Shares</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20"><FONT STYLE="color: Black">The
Purchased Shares are currently held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered
into between the Company and the Trustee. The Trustee shall not exercise the voting rights attached to the Shares held on trust by it.
As at the date of this announcement, no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial
grant of the 2022 Awards on June 23, 2022 and the further grants of the 2022 Awards on May 4, 2023, September 2, 2024, June 27, 2025,
November 26, 2025 and April 20, 2026 as disclosed in the Announcements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 40%; font-size: 10pt">By Order of the Board</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><B>Ascentage Pharma Group International Dr. </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><B>Yang Dajun</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><I>Chairman and Executive Director</I></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #231F20"><FONT STYLE="color: Black">Suzhou, People&rsquo;s Republic
of China, May 28, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #231F20"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20">As at the date of this announcement,
the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong<FONT STYLE="font-size: 10pt"><SUP>Note
1</SUP></FONT> as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky<FONT STYLE="font-size: 10pt"><SUP>Note
2</SUP></FONT>, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.</P>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #231F20"><FONT STYLE="color: Black"><I>Notes:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; color: #231F20"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="color: Black"><I>1.</I></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="color: Black"><I>Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities
    and Exchange Commission and Nasdaq corporate governance requirements.</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; color: #231F20"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2%"></TD><TD STYLE="width: 3%"><FONT STYLE="color: Black"><I>2.</I></FONT></TD><TD STYLE="width: 95%"><FONT STYLE="color: Black"><I>Dr. David Sidransky is the
                                            Lead Independent Non-Executive Director of the Company.</I></FONT></TD></TR></TABLE>
<P STYLE="margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !0 /T# 2(  A$! Q$!_\0
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M-S<N9)I(@78C&36LJ3C!3?4RC54I.*Z&I11161J%%%% !1110 4444 %%%%
M'B6MO]M\97>XY#WOE_@&"_R%>MZ=ISVFH:C<RLK-=2J5V]D50 #^M8DGP]L9
M/$!U(W$NPR^<;? P6SGKUQGM76UTUJJDDH]CGI4FFW+N%<#\3-8V0P:5$W,G
M[V;']T?='Y\_A7=3SQVT$DTK!8XU+LQ[ <FO#M5U"76M8GNWSNG?Y5/\*]%'
MX#%/"PO+F>R%B9VCRK=G6_#VR@LX;K6KYTCC'[F(O_X\1^@_.L*YTVT_M.XD
MMBYMS(6B4C;@9S5RSMKF\^SV5N'F,:[40=%'<^W/>M3Q!X3FT[PR]VDY:YC(
M:54Z!.AQWXX.:\UXNOBZKC1?+%Z7/26$P^$I*5=<TEK8;I6BWGB*5[A[@>6K
M;7E=MS9] *UM<6S\%Z*+BS@66]D81QR3#<0<9)_ #H*YWX=:Q]AUIK&1L17@
M^7/:0=/S&1^5=KXPT%]?T7R8"HN(G$D6XX#'&"/Q!K>G@:6'JI2U\V<]3'5<
M12?+IY(\Y@OO%&L-)-:W&HW&P_,86("GTP,#\*ZOP'J6NWE]<P:B\KV\"?,9
MTPZN3P,]>F>M<99ZEK'A6\>.,RVLA/SPRI\K?@>OU%>A>%?&T6O2BTNHA!>X
MR IRD@'7'H?:O2KI\KM%6/.H-<RO)W$\8^,1H.VTLU62^==QW<K$.Q([GT%>
M?MKNOW[O*M[?R;>6\HL%7\%X%1^))GN/$^HO*Q#?:&7)[ ' _05[)IEA;Z9I
M\-K:(JQ(H Q_%[GW-2^6A!:7;*7-7F];)'"^"O%^I76IQZ=>[[Q) <2X^>/'
M<GN/K6MXS\9-HK"QT\*UXR[G=AD1 ]..Y-=+;:;9V=Q//;6T44LYS*ZK@L?>
MO&?$,DEUXEU!GR7:Y=0/H< ?H*FE&%:I>UDBJCG2IVO=E])_%E];F_BEU.2$
M<^8C$#'L!U'T%;O@_P <W,M[%I^K2"593MBG(PP;L&]<^M1Q:MXXAB2*/3BJ
M(H55%L, #H.M8#>'=?FOC<'2KA)'E\SY4"J"3GCT%;-1FFI67:QDG*#3C<[+
MXBZM?Z7'8?8+J2W\POO*8YP!C^=<QJ/CK6=3$4%J[6X"A2(!EY&QR<]?P%;?
MQ2SY>EYZYD_DM3_#&R@_LVZO#&#<&;R]YZA0 <#TZUE#DA14VKLTGS2K."=C
MCXO$>O:9<@F^NUD')CG)(/U5J]*T;Q#_ &[X9GO(5\NZC1U=%YVN%R,>QX(K
M+^)UM$VB6]P4'FI.$#=\$'(_050^%DC>9J4>?EQ&V/?YJ*G+4I>TM9H(<U.K
M[.]TSA[R\N[Z?SK^626<J 6D&#CM6A8Z]KELD$%K=W:PH0J(JY7&>G2M#XB?
M\C;)_P!<8_ZUZ#X/_P"12TW_ *XBM:E51IJ7+N94Z3=1QOL)XNNKZR\-W%QI
MKE)T*\JNX[<@' _&O./-\77:F4'6'7KD!U'Z8KT3Q5XGC\-VB$1^=<S$B*/.
M!QU)]JX^V\6>+M3WS6%L)(E.#Y5OE1[9)YK"@I*%[+U9M7<7.UWZ(B\*^,M1
MM]7@M-0N'N+:9Q$?-.6C)X!!Z]>H->C:MJ<.CZ9->W&=D2YP.K'L!]37C#SS
M3Z^)KA/+G>Z#2(%V[6W#(QVYKT?XDQR/X7#("52X1GQZ<C^9%57IQ=2/2XJ-
M22A+K8XB^\6:[K-V?*N)XP?N06N1@?AR?K5%M9U=)"CZC>HP."'F88^N3Q77
M?#"XLX_ML4C(EV[*5W'!9,=!^/\ 2L_XD7%G/KL(MF1Y4BVSLG/.> ??&:VC
M*/M/9J)C*+]G[1R.N\/+>>'_  ]<W/B"[\T F4-YADVK@<9[Y/IZUQ=_XOUW
MQ!?^3IQFA1B?+@M_OD>[#G^0K2\037"?#/1XY=P,I0-GNH!*_P A6#X9GUNT
M>XGT*U\YB DC>4'V]P/;_P"M6=."M*;M?\#2I-W4%>WXDPUSQ-X<O$%W-=*3
M\WE77SJX_'^AKTWP_K<.OZ4EY$NQL[9(\Y*,.HKSS6%\6Z[!'#?Z9(RQMO4K
M %(.,=<UT/P[TS4-,@OUOK:2W5W0H)!C)P<D?I4UXQ=/FTOY%4924^76WF=K
M1163/XHTBUU0:=->QI<DA=I!P">@)Z UQ)-['8VEN8/Q(UC[+I4>G1-B6[.7
MQVC'7\S@?G7'>%=!N-:OR85Q'%]Z1APN?YGVKU._T72M4N5:^M()YU3 WC+!
M<_RS5FQT^UTVW\BR@C@BR6VH,#/K6KJ+V+I+KN91@U655]-B+2])MM)M_*MD
MY/WW/WG/O5N:))X7BE4-&ZE6![@\&GT5A&*BK1-Y2<G>1X9J=C-H.N36RL5D
MMI0T;^W53^6*]*U'Q@L'@R+5[=5,\^U$4C*K)WS],']*V;_0=,U.<37UC#/*
M!M#.O./2H%&B:<JZ0/LD2R=+8XPV?4'UKKG6C44;K5')&DZ;=G9,X:_\?PZM
MI,MKJ&D1R2LA"N'^56[,,C(_.LOP393W?BFS: $K;MYDK=E7!Z_7I7HS^"/#
M\DF\Z;&#Z*S*/R!K5L=.M--@\FRMXX(_1%QGZ^M4\1",7&"W$J$Y24IO8\W^
M('AR:TU*35((RUK<<RD#_5OWS['U]:@TKXA:EIM@EJ\4-RL8VH\A(8#L#CK7
MJS*'4JP!4C!!&0:Q9O!>@SRF1]-B#$Y.PLH/X XI1Q$7%1J*]ARH24N:F[7.
M-\+^(]>U7Q4"LAGBE/[^,C$<2>H]#Z>M0>/_  _+8:M)J,2%K2Y.YF'_ "S?
MN#Z9ZY^M>F6.G6FF0>38V\<$?HBXS]?6IY(TE1DD571A@JPR"*GZPHSYHJR'
M[!N'+)ZGF.G_ !*O[2R6"XM8KF1%VB4N5)^HQR:U/"/C/4=8UR2UO(1)'*"R
MF),"#'K['U/>M^3P5H$LOF-IL8)Y(5F4?D#BM2RTZTTV'RK*WB@C[A%QGZ^M
M.=2BT^6.K"%.JFN:6B.(^*?W-,^LG_LM7?AC_P B_<_]?)_]!6NHO]*L=45!
M?6L5P$)*^8N=N?2G6.G6FFPF*RMXX(RVXJBX!/K4.JO9>S*5)^UYSF?B9_R+
M,7_7TG\FK)^%G_'SJ7^Y'_-J[V]L+74H/)O8(YXLAMKC(R.]1V&D6&E[_L-I
M#;^9C=Y:XSCI0JJ5)TP=)NJIGFOQ(MWB\3+,P.R:!=I]<$@C^7YU!I_CW4M+
MTNWLH8K;RX,#>RDL5SG'7'XUZEJ&EV6JP"&_MXYXP<@,.A]CVJA:^$-#LY \
M6FPEAT+Y?_T+-:QQ$.11FKV,Y4)\[E!VN<C\28&N4TW5(@6MGCV;L?=SAES]
M?Z5%X<\>6^BZ EE-9R22P[MA0@*^23SZ=?>O2)K>&X@:":))(F&"C+D$?2L=
M/!6@1S>8NFQ$@YPQ8K^1.*F-:#AR36Q4J,U/G@]SRA[B6\UM+R:/8US<";&"
M <OV]178?$;Q%.ES_8]NVR'RPTY[OGHOTQS7;7.C:=>2PR7%E!(\  C+(/D
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M%_7W%S2+R^U R75S;BUM7 \B%Q^](_O-Z9["M2BBN)N[/02L@HHHI#"BBB@
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%%9EG_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
